Protocol Ledger

NCT05092841 · Phase III · COMPLETED

A Study to Assess the Efficacy and Safety of PXT3003 in Charcot-Marie-Tooth Type 1A

Interventional Phase III clinical trial protocol NCT05092841 sponsored by Tasly GeneNet Pharmaceuticals Co in Rare Genetic, Women's Health, and Other, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2021-09-28 Enrollment: 176 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT05092841
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)176 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT05092841
Protocol FieldVerified Registry Value
NCT IdentifierNCT05092841
Consolidated Lead SponsorTasly GeneNet Pharmaceuticals Co
Therapeutic Condition CohortRare Genetic, Women's Health, and Other
Clinical Trial PhasePhase III
Overall Recruitment StatusCOMPLETED
Registered Enrollment176 participants (ACTUAL)
Registered Start Date2021-09-28
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Search related sites and sponsors in the Interactive Directory, explore Rare Genetic, Women's Health, and Other Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI